48 Results for "
URAT1
" in MedChemExpress (MCE) Product Catalog:
Products (48)
48 Results for "URAT1" in MCE Product Catalog:
5
Research Areas:
Lesinurad is a URAT1 and OAT inhibitor, is determined to be a substrate for the kidney transporters OAT1 and OAT3 with Km values of 0.85 and 2 µM, respectively.
5
5 Cited Publications
Synonyms: RDEA-594 sodium
Research Areas:
Lesinurad sodium is a URAT1 and OAT inhibitor, is determined to be a substrate for the kidney transporters OAT1 and OAT3 with Km values of 0.85 and 2 μM, respectively.
2
Target:
Research Areas:
Verinurad (RDEA3170) is a highly potent and specific URAT1 inhibitor with an IC50 of 25 nM [1].
Synonyms: XNW3009
Target:
Research Areas:
Xininurad is a potent orally active URAT1 inhibitor with an IC50 of 7.17 nM. Xininurad inhibits URAT1 activity to reduce serum uric acid levels and increase urinary uric acid excretion. Xininurad can be used for the research of hyperuricemia and gout [1].
Target:
Research Areas:
URAT1 inhibitor 8 (example 247) is a potent URAT1 inhibitor, with an IC50 of 0.001 μM. URAT1 inhibitor 8 can be used for gout research [1].
Cat. No.: HY-175645
CAS No.: 2994637-53-3
Research Areas:
NLRP3/URAT1-IN-1 is an orally active double inhibitor of NLRP3 and URAT1 (IC50 = 3.81 μM). NLRP3/URAT1-IN-1 inhibits IL-1β release in LPS (HY-D1056) and ATP-stimulated mouse bone marrow-derived macrophages (BMDMs), with an IC50 of 2.61 μM. NLRP3/URAT1-IN-1 reduces serum uric acid (SUA) and alleviates liver/kidney damage in mice with acute hyperuricemia (HUA). NLRP3/URAT1-IN-1can be used for the study of gout and hyperuricemia [1].
Synonyms: UR-1102; URC-102
Research Areas:
Epaminurad (UR-1102) is an orally active, potent and selective URAT1 (urate transporter 1) inhibitor, with a Ki of 0.057 μM. Epaminurad quite modestly inhibits OAT1 and OAT3 (organic anion transporter). Epaminurad is a uricosuric agent. Epaminurad can be used for gout and hyperuricemia research [1].
Cat. No.: HY-163431
CAS No.: 3012586-38-5
Target:
Research Areas:
URAT1 inhibitor 10 (Compound 23a) is a URAT1 inhibitor. URAT1 inhibitor 10 has oral efficacy and low cytotoxicity. URAT1 inhibitor 10 has high selectivity for OAT1 [1].
Cat. No.: HY-153706
CAS No.: 2102670-94-8
Target:
Research Areas:
URAT1 inhibitor 5 (compound 16) is a potent URAT1 inhibitor. URAT1 inhibitor 5 can be used in research of hyperuricemia [1].
Cat. No.: HY-176139
CAS No.: 2816864-54-5
Target:
Research Areas:
URAT1 inhibitor 13 (compound 22k) is a potent URAT1 inhibitor. URAT1 inhibitor 13 can be used in the study of gout [1].
Target:
Research Areas:
URAT1 inhibitor 3 is a potent, orally active, selective URAT1 inhibitor with an IC50 value of 0.8 nM. URAT1 inhibitor 3 has urate-lowering efficacy. URAT1 inhibitor 3 can be used in research of gout and hyperuricemi [1].
Cat. No.: HY-153970
CAS No.: 1632002-28-8
Target:
Research Areas:
URAT1 inhibitor 7 (compound 10f) is a potent URAT1 inhibitor, with an IC50 of 12 nM. URAT1 inhibitor 7 exhibits microsomal stability (HLM <13 µL/min/mg). URAT1 inhibitor 7 also inhibits CYP2C9, with an IC50 of 4.2 μM. URAT1 inhibitor 7 can be used for gout research [1].
Target:
Research Areas:
URAT1 inhibitor 1 (1g) is a uric acid transporter 1 (URAT1) inhibitor, with an IC50 of 32 nM. URAT1 inhibitor 1 has potential to treat hyperuricemia associated with gout [1].
Cat. No.: HY-153969
CAS No.: 2244807-49-4
Target:
Research Areas:
URAT1 inhibitor 6 (Compound 1h) is a potent URAT1 inhibitor (IC50: 35 nM for hURAT1). URAT1 inhibitor 6 is 200- and 8-fold more potent than parent Lesinurad (HY-15258) and Benzbromarone (HY-B1135). URAT1 inhibitor 6 can be used for research of inflammation [1].
Cat. No.: HY-160265
CAS No.: 2251727-90-7
Target:
Research Areas:
URAT1 inhibitor 9 (Compound 24) is an URAT1 inhibitor that can be used in the study of gout or hyperuricemia [1].
Cat. No.: HY-143906
CAS No.: 2803951-18-8
Target:
Research Areas:
URAT1 inhibitor 2 is an orally active and potent URAT1 and CYP isozyme inhibitor, with IC50 values of 1.36 μM, 16.97 μM, 5.22 μM for URAT1-mediated 14C-UA uptake, CYP1A2 and CYP2C9, respectively. URAT1 inhibitor 2 is a promising agent candidate in the study of hyperuricemia and gout [1].
Cat. No.: HY-152033
CAS No.: 2700292-02-8
Research Areas:
URAT1 inhibitor 4, a Lesinurad derivative, is a potent and orally active URAT1 inhibitor with an IC50 of 7.56 μM. URAT1 inhibitor 4 has higher in vivo urate-lowering efficacy than Lesinurad (HY-15258) [1].
Cat. No.: HY-168740
CAS No.: 2416416-13-0
Target:
Research Areas:
URAT1 inhibitor 11 (Compound 7) is a URAT1 inhibitor with an IC50 value of 0.18 μM. URAT1 inhibitor 11 exhibits potent hypouricemic effects in hyperuricemic zebrafish induced by Potassium oxonate (HY-17511) and Xanthine sodium salt (HY-W017389) [1].
Cat. No.: HY-158056
CAS No.: 2883011-18-3
Research Areas:
URAT1/GLUT9-IN-1 (compound 29) can inhibit both uric acid transporter 1 (URAT1) (IC50=2.01 μM) and glucose transporter 9 (GLUT9) (IC50=18.21 μM). URAT1/GLUT9-IN-1 exhibits favorable pharmacokinetic properties and oral bioavailability. URAT1/GLUT9-IN-1 can be uesd for gout and hyperuricemia research [1].